SYRE vs TRMB

Trimble Inc.

(TRMB) offers the better valuation at 35. 3x trailing P/E (20. 0x forward), making it the more compelling value choice. Analysts rate Spyre Therapeutics, Inc. (SYRE) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Trimble Inc.

(TRMB) delivered a total return of -22. 0%, compared to -59. 6% for Spyre Therapeutics, Inc. (SYRE). Over 10 years, the gap is even starker: TRMB returned +166. 8% versus SYRE's -66. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Trimble Inc.

(TRMB) is the lower-risk stock at 1. 46β versus Spyre Therapeutics, Inc. 's 2. 06β — meaning SYRE is approximately 40% more volatile than TRMB relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Spyre Therapeutics, Inc.

grew EPS 37. 7% year-over-year, compared to -71. 3% for Trimble Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Trimble Inc.

(TRMB) is the more profitable company, earning 11. 8% net margin versus -198. 3% for Spyre Therapeutics, Inc. — meaning it keeps 11. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TRMB leads at 16. 9% versus -256. 0% for SYRE. At the gross margin level — before operating expenses — TRMB leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for TRMB: 53.

6% to $95. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Trimble Inc.

(TRMB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+166. 8% 10Y return). Spyre Therapeutics, Inc. (SYRE) carries a higher beta of 2. 06 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TRMB: +166. 8%, SYRE: -66. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SYRE (Healthcare) and TRMB (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.